Clinical Pharmacogenetics Implementation Consortium
What is CPIC?
The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.
One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.
CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications). CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.
CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.
Additionally, the College of American Pathologists (CAP) has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”
CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.
Team
CPIC Co-Principal Investigators
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital
Teri E. Klein, Ph.D.
Stanford University
Co-Investigator
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital
CPIC Informatics Co-Directors
Michelle Whirl-Carrillo, Ph.D.
Stanford University
James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital
Stanford CPIC Coordinator
Michelle Whirl-Carrillo, Ph.D.
Stanford University
Steering Committee
Teri E. Klein, Ph.D.
Stanford University
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital
Michelle Whirl-Carrillo, Ph.D.
Stanford University
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital
Dan M. Roden, M.D.
Vanderbilt University
Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH
Larisa Cavallari, Pharm.D.
University of Florida
Stuart A. Scott, Ph.D.
Stanford University and Stanford Healthcare
Sara Van Driest, M.D., Ph.D.
Vanderbilt University
Scientific Advisory Board
Julie A. Johnson, Pharm.D.
University of Florida
Gwendolyn A. McMillin, Ph.D.
ARUP Laboratories
Robert Nussbaum, M.D.
University of California, San Francisco
Heidi Rehm, Ph.D.
Partners Healthcare
Marc S. Williams, M.D.
Geisinger
Sandy Aronson
Partners Personalized Medicine
Justin B. Starren, M.D., Ph.D.
Northwestern University
Houda Hachad, Pharm.D., M. Res.
AccessDx/Medtek21
Andrea Gaedigk, Ph.D.
Children’s Mercy
News & Announcements
- Dan Hertz (DLHertz@med.umich.edu) and the DPYD Implementation Team are collecting information from sites and clinicians in the USA that conduct DPYD genetic testing prior to fluoropyrimidine chemotherapy treatment. If this applies to you, please complete this brief (
- The Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase have jointly published recommendations on what constitutes the minimum panel of variant alleles (tier 1) and an extended panel of variant alleles […]
- Phenoconversion in the PGx context is a drug-drug interaction that impacts a drug metabolizing phenotype such that it mimics the effects of a metabolizer genotype (see blog from October 2022). Historically much of the discussion on phenoconversion has focused on CYP2D6.A new paper in Frontiers in Pharmacology investigates the phenoconversion effects of different CYP2C19 inhibitors […]
- The ClinGen Pharmacogenomics Working Group (PGxWG)'s anonymous survey will close soon after this Friday, June 30, 2023. Our goal is to gather opinions and feedback regarding the criteria and terminology that should be used to define clinical validity and actionability for pharmacogenes and variants. If you have not yet had the chance to fill it out or pass […]
- At the upcoming PGRN 2023 annual conference in Memphis, Dr. Teri E. Klein, the principle investigator for PharmGKB, ClinGen, CPIC and PharmCAT, will hold a town hall discussion on ClinPGx: a single integrated resource for Pharmacogenomics (PGx). Dr. Klein will discuss the challenge of the separation of pharmacogenomic resources from clinical genomic resources, and present […]